GlassScriptPhysician profile
Diana Donovan
NPI 1649358342
$1,500.24
in general payments reported to CMS, 2019-2025
13 companies · $756 in 2025
The $756 reported for 2025 was more than what 80% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $225 · 2022: $107 · 2023: $73.60 · 2024: $339 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $284.68 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $264.45 | 2024-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $206.92 | 2021-2025 | Lynparza, Imfinzi, Calquence |
| E.R. Squibb & Sons, L.L.C. | $139.03 | 2021-2025 | Opdivo |
| Janssen Biotech, INC. | $137.06 | 2021-2024 | Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $103.07 | 2025 | |
| Pulmonx Corporation | $97.44 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Exelixis INC. | $88.41 | 2025 | Cabometyx |
| Glaxosmithkline, LLC. | $77.32 | 2025 | Ojjaara |
| Abbvie INC. | $33.35 | 2024 | |
| Incyte Corporation | $25.12 | 2023 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $21.78 | 2023 | |
| Celgene Corporation | $21.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.